ICAP
AC-10 - 核仁颗粒型
  简体中文 English
同义词 核仁斑点状 nucleolar speckled
描述

间期细胞核仁产生密集、清晰的颗粒状荧光,分裂中期细胞胞浆内最多可见5对明亮的核仁组成体(NOR),分裂期细胞胞浆可呈现微弱荧光。例如抗NOR-90抗体,抗RNA聚合酶I抗体。

Densely distributed but distinct grains seen in the nucleoli of interphase cells. In metaphase cells, up to 5 bright pairs of the nucleolar organizer regions (NOR) can be seen within the chromatin body. The cytoplasm of mitotic cells may be slightly positive. e.g. anti-NOR-90, anti-RNA polymerase I

抗原相关性 RNA聚合酶I,hUBF/NOR-90 RNA polymerase I, hUBF/NOR-90
临床相关性
一级信息
关于临床相关性和缩写列表
Clinical Relevance
First level information
About Clinical Relevance & List of Abbreviations

►AC-10核型可以在多种情况下看到,包括系统性硬化症、雷诺现象、干燥综合征和癌症(52-56)

►如果在上述情况的患者血清中发现AC-10核型,则随后应考虑进行抗NOR90 (hUBF)抗体检测;该抗原包含在疾病特异性免疫检测中(例如,系统性硬化症抗体谱)(54-55)

►虽然AC-10与抗RNApol I抗体相关,但这些抗体几乎总是与抗RNApol III抗体共存,显示AC-5核型;因此,如果临床怀疑有系统性硬化症,建议对抗RNApol III抗体进行随访检测(参见AC-5);针对抗RNApol I抗体的特异性免疫测定还没有商业试剂盒(52,53,57)

*实用的炎症性肌病谱、系统性硬化症谱和自免肝疾病谱(扩展版)检测可能仅限于专业的临床实验室。


► The AC-10 pattern can be seen in various conditions, including SSc, Raynaud’s phenomenon, SjS, and cancer (52–56)

► If the AC-10 pattern is observed in the serum of patients with conditions mentioned above, follow-up testing for anti-NOR90(hUBF) antibodies is to be considered; the antigen is included in disease specific immunoassays (i.e. SSc profile*) (54, 55)

► While AC-10 is associated with anti-RNApol I antibodies, these antibodies almost always coexist with anti-RNApol III antibodies which reveal the AC-5 pattern; therefore, if SSc is clinically suspected, it is recommended to perform a follow-up test for anti-RNApol III antibodies (See also AC-5); specific immunoassays for anti-RNApol I antibodies are currently not commercially available (52, 53, 57)

*Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories.


一级信息参考文献 First level information references

52. Reimer G, Rose KM, Scheer U, et al. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 1987;79:65–72.

53. Kuwana M, Kaburaki J, Mimori T, et al. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993;91:1399–404.

54. Fritzler MJ, von Muhlen CA, Toffoli SM, et al. Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. J Rheumatol 1995;22:521–4.

55. Fujii T, Mimori T, Akizuki M. Detection of autoantibodies to nucleolar transcription factor nor 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 1996;39:1313–8.

56. Imai H, Ochs RL, Kiyosawa K, et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992;140:859–70.

57. Yamasaki Y, Honkanen-Scott M, Hernandez L, et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 2006;54:3051–6.


52. Reimer G, Rose KM, Scheer U, et al. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 1987;79:65–72.

53. Kuwana M, Kaburaki J, Mimori T, et al. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993;91:1399–404.

54. Fritzler MJ, von Muhlen CA, Toffoli SM, et al. Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. J Rheumatol 1995;22:521–4.

55. Fujii T, Mimori T, Akizuki M. Detection of autoantibodies to nucleolar transcription factor nor 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 1996;39:1313–8.

56. Imai H, Ochs RL, Kiyosawa K, et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992;140:859–70.

57. Yamasaki Y, Honkanen-Scott M, Hernandez L, et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 2006;54:3051–6.


二级信息 Second level information


None

二级信息参考文献 Second level information references


None

FAQ
No FAQ received
 
 

Online since 19 May 2015